Back

IJOPP · Lens · Potential Drug-Drug Interactions and Gender-Based Comparative Analysis of Chemotherapy-Related Side Effects in Oncology Patients: A Prospective, Comparative Study at a Tertiary Care Hospital in Urban India

PDF

Article · Volume 18, Issue 4 · pp. 410–418

Potential Drug-Drug Interactions and Gender-Based Comparative Analysis of Chemotherapy-Related Side Effects in Oncology Patients: A Prospective, Comparative Study at a Tertiary Care Hospital in Urban India

Trupti Tuse1, Rahul Surve1, Ketakee Gosavi1, Khushal Madanlal Ghanchi1, Tarun Singh1

  1. 1Department of Pharmacy Practice, Abhinav Education Society’s College of Pharmacy, Narhe, Pune, Maharashtra, INDIA..

Abstract

Background: Cancer patients often receive multiple medications, leading to Potential Drug-Drug Interactions (pDDIs) that may affect treatment outcomes. Chemotherapy-related side effects may also vary between genders, necessitating an understanding of these variations to improve patient care.Materials and Methods: This prospective, comparative study was conducted over 8 months (September 2023 to March 2024) at a tertiary care hospital in Urban India. A total of 273 patients were analysed for pDDIs and 213 patients were assessed for chemotherapy-related side effects. Patient data were collected using a structured data collection form. Drug interactions were assessed using Lexicomp® Solutions and data were analysed using SQL software. Statistical analysis, including chi-square tests, was performed using Microsoft Excel, with p-values < 0.05 considered statistically significant.Results: A total of 506 Potential Drug-Drug Interactions (pDDIs) were identified, with 88.2% of females and 90.3% of males experiencing at least one interaction. Pharmacodynamic interactions were more common (304 cases) compared to pharmacokinetic interactions (202 cases). The most frequent interaction was Aprecap-Dexa (11.06%), followed by Carboplatin-Paclitaxel (8.3%). Side effects were more prevalent in females, especially haematological side effects such as neutropenia (69% in females vs. 65.7% in males) and thrombocytopenia (24.6% in females vs. 23.28% in males). Non-haematological side effects, including indigestion and acidity, were also higher in females compared to males.Conclusion: This study highlights a high prevalence of pDDIs in oncology patients, emphasizing the need for proactive monitoring and clinical pharmacist involvement. Gender-specific differences in chemotherapy side effects suggest the need for personalized supportive care interventions to optimize treatment outcomes.

Keywords: Anti-Cancer Therapy; Drug-Drug Interactions (DDIs); Gender Differences; Side Effects

The full text of this article is available as a PDF. Open the PDF.